Currently Recruiting4 studies
−+Perioperative care (non-transplant), Transplant – perioperative · Hamilton Health Sciences Corporation
The BRACKETS pilot trial is a multicentre, randomized controlled trial evaluating the feasibility and safety of prophylactic preoperative tranexamic acid (TXA) and desmopressin in patients with advanced CKD or AKI undergoing noncardiac surgery. Utilizing a partial factorial design, the study compares TXA versus placebo and desmopressin versus placebo to address the increased bleeding risk associated with impaired primary hemostasis in this population. The trial aims to provide preliminary efficacy data and pharmacokinetic profiles to inform dose selection for a larger international phase. Investigators seek to determine if these generic agents reduce perioperative bleeding complications in a high-risk cohort typically excluded from major surgical trials.
Transplant – perioperative · Alp Sener
AAlp Sener
This single-blind randomized controlled trial evaluates the efficacy of sodium thiosulfate (STS) as an additive to cold organ preservation solutions for patients undergoing kidney transplantation. Investigators aim to mitigate ischemia-reperfusion injury and delayed graft function by utilizing STS as a clinically viable hydrogen sulfide donor during the ex vivo pumping process. The study population consists of transplant recipients receiving kidneys from deceased donors, a group at high risk for reduced graft viability due to prolonged cold storage and metabolic demand. Following the intervention, participants are monitored for one year via serial blood and urine collections to assess graft function and long-term clinical outcomes.
Transplant – post-transplant care, Transplant – perioperative · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
AAlp Sener
This randomized, double-blind, pilot study evaluates the safety and efficacy of human milk oligosaccharides (HMO) in approximately 60 patients undergoing kidney transplantation. Participants receive either HMO prebiotic sachets or placebo for 12 weeks to determine if prebiotic therapy reduces delayed graft function and mitigates gastrointestinal side effects associated with post-transplant immunosuppression. The study monitors graft function through serial blood and urine samples, while microbiome changes are assessed via fecal analysis at six time points. Researchers utilize SF-36 and GI health questionnaires to measure quality of life and treatment tolerability over a six-month follow-up period. The primary objective is to determine if HMO-driven production of short-chain fatty acids improves the gut-kidney axis and stabilizes systemic inflammatory responses in this population.
Transplant – perioperative · Western University, Canada
EEphraim Tang
This phase III, randomized, double-blind, sham-controlled trial evaluates the efficacy of continuous transversus abdominis plane (TAP) catheter infusions for postoperative pain management in kidney transplant recipients. Investigators randomize patients to receive either a continuous infusion of ropivacaine or a saline sham via a surgically placed TAP catheter for 48 hours. Both cohorts receive a standardized multimodal analgesic regimen consisting of a PCA pump, acetaminophen, and gabapentin. The study aims to determine if regional local anesthetic delivery reduces opioid consumption and improves pain control compared to standard systemic analgesia alone in this surgical population.
